PD-1 blockade + VEGF inhibition
Normalising the tumour's blood vessels lets immune cells in, and VEGF blockade removes an immunosuppressive signal.
Standard in RCC (pembrolizumab-axitinib, nivolumab-cabozantinib), HCC (atezolizumab-bevacizumab), endometrial (lenvatinib-pembrolizumab). Ivonescimab fuses both into one molecule and beat pembrolizumab in NSCLC.
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-775 / Study 309
Shares Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum), Endometrial cancer, Pembrolizumab.
- TrialHARMONi-3
Shares Ivonescimab, Pembrolizumab, Non-small-cell lung cancer.
- PersonHeather A. Wakelee
Shares Atezolizumab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PairingCaution: PD-1 rechallenge after progression on immunotherapy (RCC)
Shares Anti-angiogenic therapy, Atezolizumab, Renal cell carcinoma, Immune checkpoint inhibitors.
- ProductLenvatinib
Shares Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum), Use imaging to find the window when tumour blood vessels are working properly, VEGF angiogenesis, Anti-angiogenic therapy.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares Atezolizumab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaImmunotherapy downstaging to transplant with a safe washout
Shares Atezolizumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
- TrialHARMONi-2
Shares Ivonescimab, Pembrolizumab, Non-small-cell lung cancer.